Ophthotech Corp. (OPHT)

[-Trillion-]

What's Next:
If you're looking for a reason to hang on to the company's shares, it is worth pointing out that Ophthotech had more than $320 million in cash on its balance sheet as of the end of September. That's $100 million more than the company's current market capitalization. In addition, it has another drug candidate in its pipeline -- Zimura -- that is currently in phase 2/3 trials as a potential treatment for geographic atrophy, an advanced form of dry AMD. Thus, while the stock's drop today is deserved, it is possible that the markets are overreacting.